Literature DB >> 11875088

Retrievable covered nitinol stents: experiences in 108 patients with malignant esophageal strictures.

Ho-Young Song1, Deok Hee Lee, Tae-Seok Seo, Sung-Bae Kim, Hwoon-Yong Jung, Jong-Hoon Kim, Seung-Il Park.   

Abstract

PURPOSE: The authors report their experience with three types of retrievable covered nitinol stents in patients with malignant esophageal strictures.
MATERIALS AND METHODS: Three types of retrievable covered nitinol stents were designed. Type A stents were placed in 45 patients, type B stents were placed in 29 patients, and type C stents were placed in 34 patients. The stents were removed with use of a stent retrieval set under fluoroscopic guidance when the stents caused complications. Stent patency, symptom relief, survival rate, and complications were analyzed relative to stent type and radiation therapy.
RESULTS: The timing of radiation and the stent type have significant effects on occurrence of complications such as stent migration and fistula formation (P =.002 and P = 0.029, respectively). Complications were significantly more frequent in patients with the type B stent than those with type A or type C stents (P =.008). Patients who underwent radiation therapy before stent placement or who underwent no radiation therapy experienced substantially less complications than those who underwent radiation therapy after stent placement (P =.005 and P <.001, respectively). The survival period was significantly longer in patients who underwent radiation therapy after stent placement than in the other groups (P =.034). Stents were removed from 15 patients (14%) 2 days to 16 weeks (mean, 4 weeks) after stent placement as a result of severe pain (n = 7), stent migration (n = 6), or stent deformity (n = 2). Stent removal was well tolerated in all patients.
CONCLUSION: Use of retrievable covered nitinol stents seems to be a safe and effective method of treatment in patients with malignant esophageal strictures. However, removal of the stents was needed in 14% of the patients because of complications. Patients who underwent radiation therapy after stent placement and those with the type B stent experienced more complications than other patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11875088     DOI: 10.1016/s1051-0443(07)61722-9

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  21 in total

1.  Clinical outcomes of using a conservative approach of late esophageal stent placement in palliation of malignant dysphagia.

Authors:  Krishdeep Singh Chadha; Michael Schiff; Michael D Sitrin; Gregory E Wilding; Hector Nava
Journal:  J Gastrointest Cancer       Date:  2010-09

2.  Retrievable esophageal stents for benign indications.

Authors:  Robert F Wong; Douglas G Adler; Kristen Hilden; John C Fang
Journal:  Dig Dis Sci       Date:  2007-06-28       Impact factor: 3.199

3.  Temporary stent placement with concurrent chemoradiation therapy in patients with unresectable oesophageal carcinoma: is there an optimal time for stent removal?

Authors:  Jung-Hoon Park; Ho-Young Song; Ju Yang Park; Jin Hyoung Kim; Yong Hee Kim; Jong-Hoon Kim; Sung-Bae Kim
Journal:  Eur Radiol       Date:  2013-02-21       Impact factor: 5.315

Review 4.  Endoscopic management and prevention of migrated esophageal stents.

Authors:  Bruno da Costa Martins; Felipe Alves Retes; Bruno Frederico Medrado; Marcelo Simas de Lima; Caterina Maria Pia Simione Pennacchi; Fabio Shiguehissa Kawaguti; Adriana Vaz Safatle-Ribeiro; Ricardo Sato Uemura; Fauze Maluf-Filho
Journal:  World J Gastrointest Endosc       Date:  2014-02-16

5.  Fluoroscopic removal of retrievable self-expandable metal stents in patients with malignant oesophageal strictures: Experience with a non-endoscopic removal system.

Authors:  Pyeong Hwa Kim; Ho-Young Song; Jung-Hoon Park; Wei-Zhong Zhou; Han Kyu Na; Young Chul Cho; Eun Jung Jun; Jun Ki Kim; Guk Bae Kim
Journal:  Eur Radiol       Date:  2016-06-21       Impact factor: 5.315

6.  The use of biodegradable (SX-ELLA) oesophageal stents to treat dysphagia due to benign and malignant oesophageal disease.

Authors:  Ewen A Griffiths; Catherine J Gregory; Kishore G Pursnani; Jeremy B Ward; Robert C Stockwell
Journal:  Surg Endosc       Date:  2012-03-07       Impact factor: 4.584

7.  Palliative stenting with or without radiotherapy for inoperable esophageal carcinoma: a randomized trial.

Authors:  Amit Javed; Sujoy Pal; Nihar Ranjan Dash; Vineet Ahuja; Bidhu Kalyan Mohanti; Sreenivas Vishnubhatla; Peush Sahni; Tushar Kanti Chattopadhyay
Journal:  J Gastrointest Cancer       Date:  2012-03

8.  Esophageal Metal Stents with Concurrent Chemoradiation Therapy for Locally Advanced Esophageal Cancer: Safe or Not?

Authors:  Yueh-Feng Lu; Chen-Shuan Chung; Chao-Yu Liu; Pei-Wei Shueng; Le-Jung Wu; Chen-Xiong Hsu; Deng-Yu Kuo; Pei-Yu Hou; Hsiu-Ling Chou; Ka-I Leong; Cheng-Hung How; San-Fang Chou; Li-Ying Wang; Chen-Hsi Hsieh
Journal:  Oncologist       Date:  2018-05-04

9.  Radiotherapy versus stenting in treating malignant dysphagia.

Authors:  Hany Eldeeb; Hend Ahmed El-Hadaad
Journal:  J Gastrointest Oncol       Date:  2012-12

10.  The efficacy of metallic stent placement in the treatment of colorectal obstruction.

Authors:  Sung Gwon Kang; Gyu Sik Jung; Soon Gu Cho; Jae Gyu Kim; Joo Hyung Oh; Ho Young Song; Eun Sang Kim
Journal:  Korean J Radiol       Date:  2002 Apr-Jun       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.